Elicio Therapeutics Inc./$ELTX
1D1W1MYTD1Y5YMAX
Capital at risk
About Elicio Therapeutics Inc.
Elicio Therapeutics Inc is a clinical-stage biotechnology company advancing novel immunotherapies for the treatment of cancer, including mKRAS-positive pancreatic cancer, colorectal cancer (CRC), lung cancer, and other mKRAS-positive cancers. The Company focuses on developing effective, off-the-shelf immunotherapies using its proprietary Amphiphile (AMP) technology, which aims to enhance the education, activation, and amplification of cancer-specific T cells to promote durable cancer immunosurveillance. Its clinical pipeline includes ELI-002 7P, a lymph node-targeted cancer immunotherapy currently being evaluated in a Phase 2 study for mKRAS pancreatic ductal adenocarcinoma (PDAC), a common form of pancreatic cancer.
- Ticker
- $ELTX
- Sector
- Health
- Primary listing
- NASDAQ
- Employees
- 33
- Headquarters
- Boston, United States
- Website
- elicio.com
ELTX Metrics
BasicAdvanced
$50M
-
-$2.17
1.86
-
Price and volume
Market cap
$50M
Beta
1.86
52-week high
$16.00
52-week low
$1.71
Average daily volume
347K
Financial strength
Current ratio
2.77
Quick ratio
2.552
Long term debt to equity
1.647
Total debt to equity
1.783
Interest coverage (TTM)
-24.00%
Profitability
EBITDA (TTM)
-37.738
Management effectiveness
Return on assets (TTM)
-77.88%
Return on equity (TTM)
-774.56%
Valuation
Price to book
5.3
Price to tangible book (TTM)
5.3
Price to free cash flow (TTM)
-0.887
Free cash flow yield (TTM)
-112.74%
Free cash flow per share (TTM)
-2.165
Growth
Earnings per share change (TTM)
-44.04%
3-year earnings per share growth (CAGR)
-58.52%
ELTX Financial Performance
Revenues and expenses
ELTX Earnings Performance
Company profitability
Upcoming events
No upcoming events
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.